Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple...

Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy ( Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium )

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer ( Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya )

Preoperative endocrine therapy in premenopausal women leads to sparing...

Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany

Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients ( Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany )

Significant clinical benefits observed with revumenib monotherapy in relapsed...

Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA

$Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia ( Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA )$

Ide-cell enhances health-related quality of life for refractory multiple myeloma

Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium

$Ide-cell enhances health-related quality of life for refractory multiple myeloma ( Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium )$

Zanidatamab, palbociclib and fulvestrant show positive results in treating...

Dr Santiago Escrivá-de-Romani - Vall d’Hebron Institute of Oncology (VHIO)...

Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC ( Dr Santiago Escrivá-de-Romani - Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Toripalimab and metronomic chemotherapy show efficacy in treating in HER2...

Dr Hongnan Mo - National Cancer Center/Cancer Hospital, Beijing, China

Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer ( Dr Hongnan Mo - National Cancer Center/Cancer Hospital, Beijing, China )

BrECADD combined with PET2-guided treatment sets a new benchmark for the...

Dr Peter Borchmann - University Hospital Cologne, Cologne, Germany

BrECADD combined with PET2-guided treatment sets a new benchmark for the treatment of newly diagnosed advanced-stage cHL ( Dr Peter Borchmann - University Hospital Cologne, Cologne, Germany )

Ponatinib is superior to imatinib in combination with chemotherapy for newly...

Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA

Ponatinib is superior to imatinib in combination with chemotherapy for newly diagnosed Ph+ ALL ( Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA )

Cancer care in Needle Hospital, Hargeisa, Somaliland

Gebrekirstos Hagos - Needle Hospital, Hargeisa, Somaliland

Cancer care in Needle Hospital, Hargeisa, Somaliland ( Gebrekirstos Hagos - Needle Hospital, Hargeisa, Somaliland )

Relapsed refractory multiple myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed refractory multiple myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

First-line chemotherapy with atezolizumab and bevacizumab significantly...

Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer ( Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

More from ecancer